Allgemeines: In seltenen Fällen kann es zum allergischen Schock mit Bewusstlosigkeit Third party trademarks used herein are trademarks of their respective owners. /viewarticle/934632
um die Bildung von Blutgerinnseln (Thromben) in "verkalkten? Cytochrom P450 2C19 (CYP2C19) Pharmakogenetik: Bei Patienten, die lang-same CYP2C19-Metabolisierer sind, wird bei empfohlener Clopidogrel-Dosierung we-niger aktiver Metabolit von Clopidogrel ge-bildet, was einen verminderten Effekt auf die Thrombozytenfunktion zur Folge hat. Clopidogrel ist ein blutverdünnender Wirkstoff, der zur Vorbeugung eines Herzinfarkts oder eines Hirnschlags und zur Behandlung von Durchblutungsstörungen der Gliedmaßen (periphere arterielle Verschlusskrankheit) eingesetzt werden kann. "Clopidogrel?
It is taken by mouth. Can you take ibuprofen when taking duration bare metal stent plavix 75 mg etken.
Next: Pregnancy & Lactation. schwanger werden, teilen Sie dies Ihrem Arzt unverzüglich mit, da die Einnahme von "Clopidogrel? Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. Controlled studies in pregnant women show no evidence of fetal risk.Factor Xa inhibitor that inhibits platelet activation by selectively blocking the active site of factor Xa without requiring a cofactor (eg, antithrombin III) for activityBlood coagulation cascade is dependent on the activation of factor X to factor Xa via the intrinsic and extrinsic pathways, which play a central role in the blood coagulation cascadeDose-dependent inhibition of factor Xa activity observed; antifactor Xa activity is also influenced by rivaroxaban; prolongs PT and aPTT and HepTestAUC: 29-56% decrease when released in proximal small intestine compared with gastric absorptionMetabolized by oxidative degradation catalyzed by CYP3A4/5 and CYP2J2; also metabolized by hydrolysisUnchanged rivaroxaban is the predominant moiety in plasma with no major or active circulating metabolites (50% higher in patients of Japanese descent)Substrate of P-gp and ABCG2 (Bcrp) efflux transporter proteinsTotal body clearance: 10 L/hr (following IV administration)Excretion: feces (21% as metabolites; 28% unchanged), urine (30% as metabolites; 36% unchanged)2.5 mg or 10 mg tablets: May take with or without food (bioavailability not significantly affected in fasted state)15 mg or 20 mg tablets: Take with food (bioavailability improves when taken with food)Tablets: Store at room temperature, 25ºC (77ºF); excursions permitted to 15-30ºC (59-86ºF)Crushed tablets in water or applesauce: Store at room temperature, 25ºC (77ºF) for up to 4 hrAdding plans allows you to compare formulary status to other drugs in the same class.To view formulary information first create a list of plans. Fragen Sie Ihren Apotheker, wie das Arzneimittel zu entsorgen ist, wenn Sie es nicht mehr benötigen. undergoing acute, in-hospital cancer treatment), active gastroduodenal ulcer in the three months prior to treatment, history of bleeding in the three months prior to treatment, or dual antiplatelet therapyNot recommended acutely as an alternative to unfractionated heparin in patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomyDo not remove an indwelling epidural or intrathecal catheter before at least 2 half-lives have elapsed (ie, 18 hr in patients aged 20-45 years and 26 hr in patients aged 60-76 years), after last administration; do not administer next dose earlier than 6 hr after removal of catheter; if traumatic puncture occurs, delay administration for 24 hrPeriodically assess renal function as clinically indicated (ie, more frequently in situations in which renal function may decline) and adjust therapy accordingly; consider dose adjustment or discontinuation of therapy in patients who develop acute renal failure while on therapyNot recommended for use in patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome (APS); for patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment has been associated with an increased rate of recurrent thrombotic events compared with vitamin K antagonist therapyUse with caution in pregnant women and only if the potential benefit justifies the potential risk to the mother and fetus (see Pregnancy)Limited available data in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomesUse with caution in pregnant patients because of the potential for pregnancy related hemorrhage and/or emergent delivery; anticoagulant effect cannot be reliably monitored with standard laboratory testingConsider benefits and risks for the mother and possible risks to the fetus when prescribing to a pregnant womanFemales of reproductive potential requiring anticoagulation should discuss pregnancy planningInsufficient data available to determine effects on breastfed child or on milk production; drug and/or its metabolites were present in milk of ratsConsider developmental and health benefits of breastfeeding along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from underlying maternal conditionA: Generally acceptable.